Literature DB >> 27216186

Multiregion Whole-Exome Sequencing Uncovers the Genetic Evolution and Mutational Heterogeneity of Early-Stage Metastatic Melanoma.

Katja Harbst1, Martin Lauss1, Helena Cirenajwis1, Karolin Isaksson2, Frida Rosengren1, Therese Törngren1, Anders Kvist1, Maria C Johansson1, Johan Vallon-Christersson1, Bo Baldetorp1, Åke Borg1, Håkan Olsson3, Christian Ingvar4, Ana Carneiro3, Göran Jönsson5.   

Abstract

Cancer genome sequencing has shed light on the underlying genetic aberrations that drive tumorigenesis. However, current sequencing-based strategies, which focus on a single tumor biopsy, fail to take into account intratumoral heterogeneity. To address this challenge and elucidate the evolutionary history of melanoma, we performed whole-exome and transcriptome sequencing of 41 multiple melanoma biopsies from eight individual tumors. This approach revealed heterogeneous somatic mutations in the range of 3%-38% in individual tumors. Known mutations in melanoma drivers BRAF and NRAS were always ubiquitous events. Using RNA sequencing, we found that the majority of mutations were not expressed or were expressed at very low levels, and preferential expression of a particular mutated allele did not occur frequently. In addition, we found that the proportion of ultraviolet B (UVB) radiation-induced C>T transitions differed significantly (P < 0.001) between early and late mutation acquisition, suggesting that different mutational processes operate during the evolution of metastatic melanoma. Finally, clinical history reports revealed that patients harboring a high degree of mutational heterogeneity were associated with more aggressive disease progression. In conclusion, our multiregion tumor-sequencing approach highlights the genetic evolution and non-UVB mutational signatures associated with melanoma development and progression, and may provide a more comprehensive perspective of patient outcome. Cancer Res; 76(16); 4765-74. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2016        PMID: 27216186     DOI: 10.1158/0008-5472.CAN-15-3476

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  43 in total

Review 1.  Targeting DNA repair in cancer: current state and novel approaches.

Authors:  Apostolos Klinakis; Dimitris Karagiannis; Theodoros Rampias
Journal:  Cell Mol Life Sci       Date:  2019-10-14       Impact factor: 9.261

Review 2.  The PI3K Pathway in Human Disease.

Authors:  David A Fruman; Honyin Chiu; Benjamin D Hopkins; Shubha Bagrodia; Lewis C Cantley; Robert T Abraham
Journal:  Cell       Date:  2017-08-10       Impact factor: 41.582

3.  Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma.

Authors:  Martin Lauss; Marco Donia; Katja Harbst; Rikke Andersen; Shamik Mitra; Frida Rosengren; Maryem Salim; Johan Vallon-Christersson; Therese Törngren; Anders Kvist; Markus Ringnér; Inge Marie Svane; Göran Jönsson
Journal:  Nat Commun       Date:  2017-11-23       Impact factor: 14.919

4.  A richer understanding of intratumoral heterogeneity: single-cell genomics put it within reach.

Authors:  Xuetao Li; Jun Hou
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

Review 5.  Tumor evolution: Linear, branching, neutral or punctuated?

Authors:  Alexander Davis; Ruli Gao; Nicholas Navin
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-01-19       Impact factor: 10.680

Review 6.  Clonal expansion in non-cancer tissues.

Authors:  Nobuyuki Kakiuchi; Seishi Ogawa
Journal:  Nat Rev Cancer       Date:  2021-02-24       Impact factor: 60.716

Review 7.  Tumour heterogeneity and resistance to cancer therapies.

Authors:  Ibiayi Dagogo-Jack; Alice T Shaw
Journal:  Nat Rev Clin Oncol       Date:  2017-11-08       Impact factor: 66.675

Review 8.  Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Med Sci (Basel)       Date:  2017-11-20

9.  Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts.

Authors:  Benjamin J Drapkin; Julie George; Camilla L Christensen; Mari Mino-Kenudson; Ruben Dries; Tilak Sundaresan; Sarah Phat; David T Myers; Jun Zhong; Peter Igo; Mehlika H Hazar-Rethinam; Joseph A Licausi; Maria Gomez-Caraballo; Marina Kem; Kandarp N Jani; Roxana Azimi; Nima Abedpour; Roopika Menon; Sotirios Lakis; Rebecca S Heist; Reinhard Büttner; Stefan Haas; Lecia V Sequist; Alice T Shaw; Kwok-Kin Wong; Aaron N Hata; Mehmet Toner; Shyamala Maheswaran; Daniel A Haber; Martin Peifer; Nicholas Dyson; Roman K Thomas; Anna F Farago
Journal:  Cancer Discov       Date:  2018-02-26       Impact factor: 39.397

10.  TERT, BRAF, and NRAS Mutational Heterogeneity between Paired Primary and Metastatic Melanoma Tumors.

Authors:  Gregory A Chang; Jennifer M Wiggins; Broderick C Corless; Mahrukh M Syeda; Jyothirmayee S Tadepalli; Shria Blake; Nathaniel Fleming; Farbod Darvishian; Anna Pavlick; Russell Berman; Richard Shapiro; Yongzhao Shao; George Karlin-Neumann; Cindy Spittle; Iman Osman; David Polsky
Journal:  J Invest Dermatol       Date:  2020-02-20       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.